ClinicalTrials.gg
CompletedNCT05393375AMUSEUpdated Jan 4, 2023

Arthrogryposis Multiplex Congenita in Pediatric Age: Correlation Between MUScular MRI and Functional Evaluation

An observational study in Arthrogryposis Multiplex Congenita, AMC-Arthrogryposis Multiplex Congenita and Pediatric ALL, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by University Hospital, Grenoble · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
97
Ages
0 Years to 18 Years
Sex
All
01

Study summary

The aim of our study is to evaluate the correlation between quantified fibro-adipous infiltration of muscles on MRI assessed by MERCURI Score and the functional abilities (deficiencies, activity limitations and social participation of pediatric patients with arthrogryposis.

Read the detailed description

Arthrogryposis multiplex congenita (AMC) is a group of rare diseases characterized by joint contractures at two or more distinct joint levels at birth. More than 400 causes are currently known. The prevalence is estimated at 1/3000 to 1/2000. Joint limitations are not progressive, but the functional consequences have a lifelong impact on patients.

Correlations between fibro-adipous infiltration and muscular deficits have already been studied in other neuromuscular diseases such as Pompe disease or Duchenne muscular dystrophy. These studies concluded on a good correlation between disease progression and severity, muscle strength, and fatty infiltration assessed by Mercuri score. The investigators concluded that muscular MRI can be used as a non-invasive biomarker and a tool to follow the progression of neuromuscular disease and help evaluate the potential effects of therapies.

The aim of this project is to define whether MRI could also be used as a tool, through the assessment of muscle fatty infiltration, to help predict the functional abilities of our patients with AMC, and more specifically the two most frequent types, Amyoplasia and distal arthrogryposis.

The investigators will analyze fatty infiltration measured by muscle MRI and quantify it using the MERCURI score which was developed by Mercuri et al. (Mercuri et al. 2002) as a semi-quantitative score to quantify fibro-adipose muscle infiltration on muscle MRI.

The investigators will evaluate musculoskeletal deficiencies and limitations of activity from data obtained from patients followed in our AMC reference center at the University Hospital Grenoble Alpes (CHUGA).

The investigators will include data from 220 children, 97 of whom have had a complete check-up including a muscle MRI. The investigators will study the existence of a correlation between this score and the deficiencies and limitations of activity.

The investigators will then evaluate the potential predictive role of fatty infiltration measured on MRI in the functional abilities of the patients.

This characterization will help to better determine and anticipate the functional capacities of our patients from the beginning of their treatment to improve their functional prognosis.

This initial work could enhance the reflection on the biomechanical modeling of joints and key functions such as standing and the acquisition of walking, in order to pave the way for rehabilitation and compensation methods that are better adapted to patient's needs.

02

Conditions studied

  • Arthrogryposis Multiplex Congenita
  • AMC-Arthrogryposis Multiplex Congenita
  • Pediatric ALL

Keywords

  • Arthrogryposis Multiplex Congenita
  • Pediatric
  • Mercuri Score
  • MRI
  • Fibro-adipous infiltration
  • Functional capacity
  • Rehabilitation
  • Retrospective observational study
03

In context

Arthrogryposis

16 studies on the registry are indexed under Arthrogryposis; 5 are open to participants now.

Browse Arthrogryposis studies →

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 837 studies on the registry; 207 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patient from PARART registry (Paediatric and Adult Registry on ARThrogryposis) evaluated in the reference center (RC) for Arthrogryposis Multiplex Congenita from 2010 until 2021). All patients were evaluated by a geneticist, and had a complete check up in the pediatric PMR unit (physical medicine and rehabilitation physician, physiotherapists, occupational and speech therapists) and had imaging analysis by whole body muscular MRI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age \< 18 at the first clinical evaluation or follow up exclusively in CHUGA pediatric rehabilitation unit
  • Clinical or molecular diagnosis of AMC established by geneticists at CHUGA
  • functional evaluation during consultation and follow-up in CHUGA pediatric rehabilitation unit
  • Muscle MRI of upper limbs, lower limbs and trunk performed at CHUGA pediatric radiology unit

Exclusion criteria

Exclusion Criteria:

  • Contra indication MRI.
  • MRI non exploitable.
  • Patient under guardianship or deprived of liberty
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
97 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1 Amyoplasia

    Patients with diagnosis of Amyoplasia

    Other: No intervention

  • Group 2 Distal Arthrogryposis

    Patients with diagnosis of Distal Arthrogryposis

    Other: No intervention

  • Group 3 Other

    Patients with diagnosis of other form of AMC

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Mercuri Scores of upper limbs, trunk, and lower limbs evaluated on muscle MRI T1

    The degree of fatty muscle infiltration was assessed on muscular MRI and quantified by Mercuri score, each muscle was staged as follows: 1. Normal appearance, 2. Mild involvement (30-60% fatty infiltration). 3. Moderate involvement (\>60% fatty infiltration). 4. Severe involvement (complete infiltration). The degree of muscle fat infiltration was assessed with at least 2 visible slices, and performed by two independent operators. In case of divergent assessments, a consensus was reached after discussion.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Muscular weakness

    Muscular weakness assessed by function (flexion, extension etc.) and not by each muscle, using the Medical Research Council (MRC) scale (from 0 to 5). The quotation was as follows: 0, no contraction; 1, flicker or trace of contraction; 2, active movement possible only with gravity eliminated; 3, active movement against gravity in the whole range of motion; 4, active movement against gravity and resistance; 5, quasi-normal strength) Evaluated by physiotherapists, occupational therapists and physician during evaluation.

    Time frame: through study completion, an average of 1 year

  2. Passive range of motion (PROM)

    Evaluated by physiotherapists; the range of motion of each movement in degrees was normalized with respect to the normal maximal movement, expressed as percentages

    Time frame: through study completion, an average of 1 year

  3. Reaching score

    Reaching capacity was assessed by ad hoc test. Patients were instructed to successively touch some body targets with upper limbs : mouth, head, forehead, neck, back, stomach, gluteal region, opposite shoulders, ipsilateral shoulders, knee, feet, "Beggar's pose", "position of the oath", and "Zenith Pose". Each gesture was marked "yes" if successful or "no" if not. Responses were transformed into a binary variable with "yes" being worth 1 and "no" being worth 0 to allow for statistical correlations afterwards. The total score was calculated on both sides averaged and ranged from 0 to 14 points

    Time frame: through study completion, an average of 1 year

  4. Ambulatory status

    Ambulatory statuses were gathered by the teams during the check-ups as well as the age of acquisition of walking if available and the use or not of technical aids

    Time frame: through study completion, an average of 1 year

  5. School status

    Type of schooling (mainstream education, adapted schooling, presence of a carer)

    Time frame: through study completion, an average of 1 year

  6. Activity limitation

    Gathered evaluating living habits and essential acts of daily life such as element of the Functional Independence Measure (FIM) : feeding, dressing, potty training, toileting, schooling, transfers, locomotion, and also existence of leisure, hobby, presence of human or technical helps.

    Time frame: through study completion, an average of 1 year

  7. Surgery History

    Surgical history for each patient

    Time frame: through study completion, an average of 1 year

  8. Human and technical Help

    use of a technical aid (manual or electric wheelchair ...), or humain for daily life activities

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • CHU Grenoble Alpes
    La Tronche, 38700, France
08

References and documents

Publications

  • Hall JG. Arthrogryposis multiplex congenita: etiology, genetics, classification, diagnostic approach, and general aspects. J Pediatr Orthop B. 1997 Jul;6(3):159-66. PubMed 9260643 ↗
  • Mercuri E, Pichiecchio A, Counsell S, Allsop J, Cini C, Jungbluth H, Uggetti C, Bydder G. A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol. 2002;6(6):305-7. doi: 10.1016/s1090-3798(02)90617-3. PubMed 12401454 ↗
  • Figueroa-Bonaparte S, Segovia S, Llauger J, Belmonte I, Pedrosa I, Alejaldre A, Mayos M, Suarez-Cuartin G, Gallardo E, Illa I, Diaz-Manera J; Spanish Pompe Study Group. Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function. PLoS One. 2016 Oct 6;11(10):e0163493. doi: 10.1371/journal.pone.0163493. eCollection 2016. PubMed 27711114 ↗
  • Quijano-Roy S, Avila-Smirnow D, Carlier RY; WB-MRI muscle study group. Whole body muscle MRI protocol: pattern recognition in early onset NM disorders. Neuromuscul Disord. 2012 Oct 1;22 Suppl 2:S68-84. doi: 10.1016/j.nmd.2012.08.003. PubMed 22980770 ↗
  • Dieterich K, Le Tanno P, Kimber E, Jouk PS, Hall J, Giampietro P. The diagnostic workup in a patient with AMC: Overview of the clinical evaluation and paraclinical analyses with review of the literature. Am J Med Genet C Semin Med Genet. 2019 Sep;181(3):337-344. doi: 10.1002/ajmg.c.31730. Epub 2019 Aug 1. PubMed 31368648 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05393375
Responsible party
Sponsor
First posted
May 26, 2022
Start date
May 1, 2022
Primary completion
Jun 1, 2022
Completion
Nov 1, 2022
Last update
Jan 4, 2023

Study contacts

Klaus DIETERICH, MD
study director · CHU Grenoble Alpes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion